Enanta Pharmaceuticals, Inc. has grown revenue −6.8% a year over three years and −7.6% a year over five. Revenue growth, 3-year annual rate: −6.8% (Biotechnology median +17%). Revenue growth, 5-year rate: −7.6%, growth has picked up over the last three years. Years of annual history on file: 15, FY2011 to FY2025, as filed.

ENTAEnanta Pharmaceuticals, Inc.

Healthcare

$12.10+9.2% 1Y

$12.10

$10.4752 weeks$16.85

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin widening (+59.9 points).

1 good, 1 neutral, 1 without data

Revenue trend+1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −8% a year.

Margin direction+59.9 points operating

Trailing-twelve-month operating margin, -92.8% now against -152.7% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ENTA growing?

Enanta Pharmaceuticals, Inc. has grown revenue −6.8% a year over three years and −7.6% a year over five.

−6.8%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −7.6%
Revenue growth, 5-year rate · −6.8% over three · growth has picked up over the last three years
Years of annual history on file: 15
Years of annual history on file · FY2011 to FY2025, as filed

Details›